CoChat
Sign Up
Cited by 224Menopause: Health Impacts and TreatmentsCancer survivorship and careSexual function and dysfunction studies

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.

Open access
Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M.J., Kramer, R., Lawrence, W., Hanfelt, J.J., Hayes, D.F.·2000·Annals of Oncology
DOI 10.1023/a:1008382706068
Open this paper in CoChat — free account

Abstract

Background Many breast cancer survivors suffer debilitating hot flashes. Estrogen, the drug of choice in perimenopausal women, is generally not recommenced to breast cancer survivors. Nonhormonal treatments are mostly disappointing. Anecdotal reports in our institution suggested that the selective serotonin-reuptake inhibitor, paroxetine hydrochloride, might be efficacious in alleviating hot flashes. Patients and methods Thirty women with prior breast cancer who were suffering at least two hot flashes a day entered a single institution pilot trial to evaluate paroxetine's efficacy in reducing the frequency and severity of hot flashes. After completing daily diaries for one week on no therapy, the women received open-label paroxetine, 10 mg daily for one week, followed by four weeks of paroxetine, 20 mg daily. The women completed hot-flash daily diaries throughout the study period, and a health-related symptom-assessment questionnaire and a quality-of-life rating scale in the first and sixth week of the study. Results Twenty-seven women completed the six-week study period. The mean reduction of hot flash frequency was 67% (95% confidence interval (95% CI): 56%-79%). The mean reduction in hot flash severity score was 75% (95% CI: 66%-85%). There was a statistically significant improvement in depression, sleep, anxiety, and quality of life scores. Furthermore, 25 (83%) of the study participants chose to continue paroxetine therapy at the end of study. The most common adverse eff…

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1008382706068

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These pilot results are comparable or superior to results of open label studies with paroxetine and venlafaxine.

    “These results are comparable or superior to results of open label studies with paroxetine and venlafaxine. 22,4,23–25”

    From Clinical hypnosis in the treatment of postmenopausal hot flashes (2013) · cites this paper as [22]

  • Self-report diaries are a valid approach to obtain data on subjective phenomena such as patient-reported symptoms.

    “the use of self-report diaries, as used in this study, has long been established as a valid approach to obtain data on subjective phenomena, such as patient-reported symptoms.”

    From Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors (2008) · cites this paper as [19]

Citations

Cites

Flagged first, then by citations

1 of the 19 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. 1999, Clinical synthesis panel on HRT [published erratum appears in Lancet 1999; 354 (9181): 870], Lancet, 354, 152

Cited by

Sorted by citations

Related

Metadata

Authors
Stearns, V., Isaacs, C., Rowland, J., Crawford, J., Ellis, M. J., Kramer, R., Lawrence, W., Hanfelt, J. J., & Hayes, D. F.
Affiliations
Georgetown University (US)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2000-01
Volume
11
Issue
1
Pages
17-22
ISSN
0923-7534 (ISSN-L)
DOI
10.1023/a:1008382706068
OpenAlex
W2111093019
Cited by
224
References
19
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 9 · 2013: 6 · 2012: 7
FWCI
16.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Fashion Footwear Association of New York
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
paroxetine, hot flashes, breast cancer survivors, selective serotonin reuptake inhibitors, menopausal symptoms, non-hormonal therapy, quality of life, depression, sleep, anxiety, sleepiness
MeSH terms
Adult, Aged, Anxiety, Breast Neoplasms, Depression, Female, Humans, Menopause, Middle Aged, Pilot Projects, Quality of Life, Surveys and Questionnaires, Sexual Behavior, Confidence Intervals, Selective Serotonin Reuptake Inhibitors, Paroxetine, Survivors, Hot Flashes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review